You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company estimated that the offering could raise between $327.2 and $376.3 million, which it would use for various corporate purposes.
The company, based in Fort Myers, Florida, said that it plans to use the net proceeds from the offering for general corporate purposes.
The company plans to offer 5.5 million shares of its common stock at $23.25 per share, raising around $127.9 million.
The company will use the proceeds for working capital and to repay around $12.4 million of its term loan.
The firm is selling more than 5.2 million shares at an offering price of $19 per share.
To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.
The firm expects to offer nearly 5 million shares and also noted that this week it entered into an amended credit facility.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
Genfit expects to use part of the gross proceeds from the offering to advance the commercial development of a diagnostic test to identify patients with nonalcoholic steatohepatitis.
Proceeds will be used for the anticipated regulatory submission of its gene panel test for urinary tract infections and drug resistance, among other things.